Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
DBV Technologies S.A. DBV.PA
$3.32
+$0.03 (0.79%)
На 18:01, 12 мая 2023
Ранг: 3
Ключевые показатели
-
Marketcap
309602059.00000000
-
week52high
5.48
-
week52low
2.25
-
Revenue
4800000
-
P/E TTM
-3
-
Beta
1.25610600
-
EPS
-1.08000000
-
Last Dividend
0.00000000
-
Next Earnings Date
31 июл 2023 г. в 06:30
Описание компании
DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies in 4 to 11 years of age children, adolescents, and adults. The milk-induced company is also developing Viaskin Milk that is in Phase I/II clinical trial for the treatment of Immunoglobulin E (IgE) mediated cow's milk protein allergy (CMPA); Viaskin Egg, a pre-clinical stage product for the treatment of hen's egg allergy; and booster vaccine for Bordetella pertussis. Its other earlier stage research programs include a vaccine for the respiratory syncytial virus, as well as treatments for Crohn's disease, celiac disease, and type I diabetes. The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Montrouge, France.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| JMP Securities | Market Outperform | Market Outperform | 21 дек 2021 г. |
| HC Wainwright & Co. | Buy | Buy | 21 дек 2021 г. |
| Morgan Stanley | Equal-Weight | Equal-Weight | 05 авг 2020 г. |
| HC Wainwright & Co. | Buy | Buy | 05 авг 2020 г. |
| Citigroup | Buy | Buy | 06 апр 2020 г. |
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Свежие комментарии
Свежие комментарии